Ignet

Gene Information

Gene symbol: PAX2

Gene name: paired box 2

HGNC ID: 8616

Related Genes

#	Gene Symbol	Number of hits
1	ACTC1	1 hits
2	ACTN4	1 hits
3	CD2	1 hits
4	CD24	1 hits
5	CD2AP	1 hits
6	CDKN1C	1 hits
7	CLDN1	1 hits
8	CLDN7	1 hits
9	CTNNB1	1 hits
10	DNMT1	1 hits
11	DPYD	1 hits
12	ENG	1 hits
13	EZH2	1 hits
14	FGF8	1 hits
15	FOXC2	1 hits
16	FOXD1	1 hits
17	GDNF	1 hits
18	JUP	1 hits
19	KRT8	1 hits
20	LMX1B	1 hits
21	MAF1	1 hits
22	MAFB	1 hits
23	MCAM	1 hits
24	MKI67	1 hits
25	MUC1	1 hits
26	NES	1 hits
27	NFKB1	1 hits
28	NPC1	1 hits
29	NPHS1	1 hits
30	NPHS2	1 hits
31	NT5E	1 hits
32	PCNA	1 hits
33	PDLIM5	1 hits
34	PECAM1	1 hits
35	POU5F1	1 hits
36	PROM1	1 hits
37	PTPRO	1 hits
38	SALL1	1 hits
39	SIX2	1 hits
40	SMAD7	1 hits
41	SULT1B1	1 hits
42	SYNPO	1 hits
43	TCF21	1 hits
44	VEGFA	1 hits
45	VIM	1 hits
46	WNT11	1 hits
47	WNT4	1 hits
48	WT1	1 hits

Related Sentences

#	PMID	Sentence
1	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
2	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
3	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
4	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
5	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
6	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
7	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
8	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
9	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
10	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
11	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
12	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
13	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
14	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
15	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
16	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
17	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
18	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
19	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
20	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
21	9916932	WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
22	9916932	One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
23	9916932	We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
24	9916932	We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
25	9916932	Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
26	11877566	WT1 and Pax2 are transcription factors involved in kidney development and phenotypic regulation of glomerular epithelial cells.
27	11877566	However, the role of WT1 and Pax2 in the development of CLs in primary FSGS is unclear.
28	11877566	Using immunohistochemistry, the expression of WT1, Pax2, and cytokeratin (CK), an epithelial marker never found in normal podocytes, was examined in 35 biopsy samples of primary FSGS.
29	11877566	Expression of WT1, Pax2, and CK was scantly positive in CSs.
30	11877566	WT1 and Pax2 are transcription factors involved in kidney development and phenotypic regulation of glomerular epithelial cells.
31	11877566	However, the role of WT1 and Pax2 in the development of CLs in primary FSGS is unclear.
32	11877566	Using immunohistochemistry, the expression of WT1, Pax2, and cytokeratin (CK), an epithelial marker never found in normal podocytes, was examined in 35 biopsy samples of primary FSGS.
33	11877566	Expression of WT1, Pax2, and CK was scantly positive in CSs.
34	11877566	WT1 and Pax2 are transcription factors involved in kidney development and phenotypic regulation of glomerular epithelial cells.
35	11877566	However, the role of WT1 and Pax2 in the development of CLs in primary FSGS is unclear.
36	11877566	Using immunohistochemistry, the expression of WT1, Pax2, and cytokeratin (CK), an epithelial marker never found in normal podocytes, was examined in 35 biopsy samples of primary FSGS.
37	11877566	Expression of WT1, Pax2, and CK was scantly positive in CSs.
38	11877566	WT1 and Pax2 are transcription factors involved in kidney development and phenotypic regulation of glomerular epithelial cells.
39	11877566	However, the role of WT1 and Pax2 in the development of CLs in primary FSGS is unclear.
40	11877566	Using immunohistochemistry, the expression of WT1, Pax2, and cytokeratin (CK), an epithelial marker never found in normal podocytes, was examined in 35 biopsy samples of primary FSGS.
41	11877566	Expression of WT1, Pax2, and CK was scantly positive in CSs.
42	12012385	These transcription factors include Pax2, WT1 (the Wilms tumor suppressor gene), Pod1 (capsulin, epicardin), Kreisler (maf-1), lmx1b, and mf2.
43	12386275	WT1 and Pax2 are transcription factors involved in kidney development and phenotypic regulation of glomerular epithelial cells.
44	12386275	To investigate the contribution of WT1 and Pax2 to the development of the CL in primary FSGS, immunohistological studies were performed using renal biopsy specimens on the expression of WT1, Pax2 and cytokeratin (CK), which is an epithelial marker but never found in normal podocytes.
45	12386275	WT1 and Pax2 are transcription factors involved in kidney development and phenotypic regulation of glomerular epithelial cells.
46	12386275	To investigate the contribution of WT1 and Pax2 to the development of the CL in primary FSGS, immunohistological studies were performed using renal biopsy specimens on the expression of WT1, Pax2 and cytokeratin (CK), which is an epithelial marker but never found in normal podocytes.
47	12488983	Recently, abnormal expression of WT1 and PAX2 was shown in the podocytes in diffuse mesangial sclerosis (DMS) associated with DDS and isolated DMS.
48	12488983	Immunohistochemical analysis of WT1, PAX2, vimentin, cytokeratin, and epithelial membrane antigen was performed in the kidney specimens obtained at autopsy or surgery.
49	12488983	Abnormal expression of WT1 and PAX2 in the EHBCE was observed in both patients, supporting our hypothesis.
50	12488983	Recently, abnormal expression of WT1 and PAX2 was shown in the podocytes in diffuse mesangial sclerosis (DMS) associated with DDS and isolated DMS.
51	12488983	Immunohistochemical analysis of WT1, PAX2, vimentin, cytokeratin, and epithelial membrane antigen was performed in the kidney specimens obtained at autopsy or surgery.
52	12488983	Abnormal expression of WT1 and PAX2 in the EHBCE was observed in both patients, supporting our hypothesis.
53	12488983	Recently, abnormal expression of WT1 and PAX2 was shown in the podocytes in diffuse mesangial sclerosis (DMS) associated with DDS and isolated DMS.
54	12488983	Immunohistochemical analysis of WT1, PAX2, vimentin, cytokeratin, and epithelial membrane antigen was performed in the kidney specimens obtained at autopsy or surgery.
55	12488983	Abnormal expression of WT1 and PAX2 in the EHBCE was observed in both patients, supporting our hypothesis.
56	15505531	The glomerular basement membrane is composed of a multitude of proteins, including collagen IV, heparan sulfate proteoglycans, and laminin, among others.
57	15505531	The exact mechanism by which nephrin controls permselectivity is not yet clear, but it is known to interact with several podocyte proteins including CD2AP, podocin, and alpha-actinin-4.
58	15505531	A host of transcription factors, especially WT1 and PAX2, play a significant role in modulating podocyte function.
59	16761013	We used Synaptopodin, vascular endothelial growth factor, and CD10 as podocyte markers, CK8 and PAX2 as PEC markers and Ki-67 as marker of cell proliferation.
60	16761013	The proliferating PAX-2 and CK8 positive cells that covered the capillary tuft were always in continuity with PAX-2/CK8 positive cells lining Bowman's capsule.
61	16761013	We used Synaptopodin, vascular endothelial growth factor, and CD10 as podocyte markers, CK8 and PAX2 as PEC markers and Ki-67 as marker of cell proliferation.
62	16761013	The proliferating PAX-2 and CK8 positive cells that covered the capillary tuft were always in continuity with PAX-2/CK8 positive cells lining Bowman's capsule.
63	16943305	The expression of podocyte-specific proteins (podocalyxin, glomerular epithelial protein-1, podocin, nephrin, synaptopodin, and alpha-actinin-4), podocyte synthesized proteins (vascular endothelial growth factor and novH), transcription factors (WT1 and PAX2), cyclin-dependent kinase inhibitor p57, and intermediate filaments (cytokeratins and vimentin) was tested.
64	16943305	WT1 and p57 were expressed in some parietal cells, whereas PAX2 was present in all or most of them, so some parietal cells coexpressed WT1 and PAX2.
65	16943305	The expression of podocyte-specific proteins (podocalyxin, glomerular epithelial protein-1, podocin, nephrin, synaptopodin, and alpha-actinin-4), podocyte synthesized proteins (vascular endothelial growth factor and novH), transcription factors (WT1 and PAX2), cyclin-dependent kinase inhibitor p57, and intermediate filaments (cytokeratins and vimentin) was tested.
66	16943305	WT1 and p57 were expressed in some parietal cells, whereas PAX2 was present in all or most of them, so some parietal cells coexpressed WT1 and PAX2.
67	17466922	In this review, the role of Wilms tumor 1 (WT1), LIM homeobox transcription factor 1, beta (Lmx1b), pod1, pax-2, kreisler, nuclear factor-kappa B (NF-kappaB), smad7, and zinc fingers and homeoboxes (ZHX) proteins in the development of podocyte disease is outlined.
68	19390481	At birth, the lambs were killed, and their kidneys were removed to study the changes in histology, podocytes, and expression of paired-box 2 (PAX2) and VEGF.
69	19579288	We found that human glomeruli deprived of the Bowman's capsule contain a population of CD133+CD146+ cells and a population of CD133-CD146+ cells expressing mesenchymal stem cell (MSC) markers and renal stem cell markers CD24 and Pax-2.
70	19579288	The CD133+CD146+ cells differed from those previously isolated from Bowman's capsule as they co-expressed endothelial markers, such as CD31 and von Willebrand factor (vWF), were CD24-negative and were not clonogenic, suggesting an endothelial commitment.
71	19579288	In addition to osteogenic, adipogenic, and chondrogenic differentiation, these cells were able to differentiate to endothelial cells and epithelial cells expressing podocytes markers such as nephrin, podocin, and synaptopodin.
72	19579288	Moreover, Gl-MSC when cultured in appropriate conditions, acquired mesangial cell markers such as alpha-smooth muscle actin (alpha-SMA) and angiotensin II (AT-II) receptor I.
73	20818613	To identify morphological and developmental changes in protein and RNA expression patterns during nephrogenesis, immunohistochemistry and quantitative real-time PCR were used to assess temporal and spatial expression of WT1, Pax2, Nestin, Synaptopodin, alpha-smooth muscle actin (α-SMA), CD31, vascular endothelial growth factor (VEGF), and Gremlin.
74	20818613	Mature podocytes expressing WT1, Nestin, and Synaptopodin were observed from the mid-third trimester through adulthood.
75	20818613	The developing glomerulus was positive for α-SMA (vascular smooth muscle) and Gremlin (mesangial cells), CD31 (glomerular endothelium), and VEGF (endothelium), and showed loss of expression of these markers as glomerular maturation was completed.
76	21160460	There was focal loss of the podocyte markers synaptopodin, glomerular epithelial protein 1 (GLEPP-1), nephrin, and vascular endothelial growth factor (VEGF), particularly at sites of capsular adhesions in otherwise histologically normal glomeruli.
77	21160460	Cells displaying the parietal epithelial cell markers PAX2 (paired box gene 2) and the cytokeratins were also positive for the proliferating cell marker, proliferating cell nuclear antigen.
78	22129965	Single and double immunostaining were performed with antibodies to the PEC protein paired box gene 2 (PAX2) and tight junction protein claudin-1, the podocyte-specific protein Wilms' tumor 1 (WT-1), and the proliferating cell protein (Ki-67).
79	22129965	The increase in PEC number was due to proliferation (increase in PAX2/Ki-67 double-positive cells).
80	22129965	Aging was accompanied by a progressive increase in the number of glomerular cells double staining for PAX2 and WT-1.
81	22129965	Single and double immunostaining were performed with antibodies to the PEC protein paired box gene 2 (PAX2) and tight junction protein claudin-1, the podocyte-specific protein Wilms' tumor 1 (WT-1), and the proliferating cell protein (Ki-67).
82	22129965	The increase in PEC number was due to proliferation (increase in PAX2/Ki-67 double-positive cells).
83	22129965	Aging was accompanied by a progressive increase in the number of glomerular cells double staining for PAX2 and WT-1.
84	22129965	Single and double immunostaining were performed with antibodies to the PEC protein paired box gene 2 (PAX2) and tight junction protein claudin-1, the podocyte-specific protein Wilms' tumor 1 (WT-1), and the proliferating cell protein (Ki-67).
85	22129965	The increase in PEC number was due to proliferation (increase in PAX2/Ki-67 double-positive cells).
86	22129965	Aging was accompanied by a progressive increase in the number of glomerular cells double staining for PAX2 and WT-1.
87	22529955	In the very early phases of primary culture, rapid changes in gene expression (e.g. of WT-1 and Pax-2) were observed.
88	22529955	Of the classical markers, synaptopodin and podoplanin expression were differentially regulated the most in primary PEC and podocyte cultures.
89	22610571	We recently found that human glomeruli deprived of the Bowman's capsule contain a population of CD133(-)CD146(+) cells that coexpress the typical mesenchymal stem cells (MSCs) markers (such as CD29, CD105, and CD73) and renal specific stem cell markers (such us CD24 and Pax2).
90	22677342	The renal protein expression of renin and angiotensin II was reduced at birth day and increased at weaning.
91	22677342	Maternal DEHP exposure also led to reduced mRNA expression of some renal development involved genes at birth day, including Foxd1, Gdnf, Pax2 and Wnt11.
92	22677342	While, the mRNA expression of some genes was raised, including Bmp4, Cdh11, Calm1 and Ywhab.
93	23769837	A subset of cells lining Bowman's capsule activated expression of the glomerular parietal epithelial cell markers paired box protein PAX2 and claudin-1.
94	23769837	A subset of labeled cells within the glomerular tuft expressed the podocyte markers Wilms tumor protein 1, nephrin, podocin, and synaptopodin.
95	24154691	Using a podocyte-specific injury model of FSGS carrying a genetic podocyte tag combined with double immunostaining by different sets of podocytes and parietal epithelial cell (PEC) markers [nestin/Pax8, Wilms' tumor-1 (WT1)/claudin1, and podocalyxin/Pax2], we investigated the direction of epithelial phenotypic transition and its role in FSGS.
96	24154691	In addition, the average numbers of double-positive cells for X-gal/Pax8, nestin/Pax8 and podocalyxin/Pax2 staining in the FSGS mice were comparable, whereas those of WT1/claudin1 were significantly increased.
97	24676634	As predicted by in silico structural modeling analyses, in vitro functional studies documented that several of the FSGS-associated PAX2 mutations perturb protein function by affecting proper binding to DNA and transactivation activity or by altering the interaction of PAX2 with repressor proteins, resulting in enhanced repressor activity.
98	25460740	Moreover, the effects of the HO-system on podocyte cytoskeletal proteins like podocin, podocalyxin, CD2-associated-protein (CD2AP) and proteins of regeneration/repair like beta-catenin, Oct3/4, WT1 and Pax2 in renal tissue from normoglycemic obese Zucker-fatty rats (ZFs) have not been reported.
99	25460740	These were associated with enhanced expression of beta-catenin, Oct3/4, WT1, Pax2 and nephrin, an essential transmembrane protein required for the formation of the scaffoldings of the podocyte slit-diaphragm, permitting the filtration of small ions, but not massive excretion of proteins, hence proteinuria.
100	25460740	Besides nephrin, hemin also enhanced other important podocyte-regulators including, podocalyxin, podocin and CD2AP.
101	25460740	Collectively, these data suggest that hemin ameliorates nephropathy by potentiating the expression of proteins of repair/regeneration, abating oxidative/inflammatory mediators, reducing renal histo-pathological lesions, while enhancing nephrin, podocin, podocalyxin, CD2AP and creatinine clearance, with corresponding reduction of albuminuria/proteinuria suggesting improved renal function in hemin-treated ZFs.
102	25460740	Moreover, the effects of the HO-system on podocyte cytoskeletal proteins like podocin, podocalyxin, CD2-associated-protein (CD2AP) and proteins of regeneration/repair like beta-catenin, Oct3/4, WT1 and Pax2 in renal tissue from normoglycemic obese Zucker-fatty rats (ZFs) have not been reported.
103	25460740	These were associated with enhanced expression of beta-catenin, Oct3/4, WT1, Pax2 and nephrin, an essential transmembrane protein required for the formation of the scaffoldings of the podocyte slit-diaphragm, permitting the filtration of small ions, but not massive excretion of proteins, hence proteinuria.
104	25460740	Besides nephrin, hemin also enhanced other important podocyte-regulators including, podocalyxin, podocin and CD2AP.
105	25460740	Collectively, these data suggest that hemin ameliorates nephropathy by potentiating the expression of proteins of repair/regeneration, abating oxidative/inflammatory mediators, reducing renal histo-pathological lesions, while enhancing nephrin, podocin, podocalyxin, CD2AP and creatinine clearance, with corresponding reduction of albuminuria/proteinuria suggesting improved renal function in hemin-treated ZFs.
106	26154924	WT1 controls metanephric mesenchyme (MM) self-renewal and proliferation mainly by regulating FGF and BMP-pSMAD signaling pathways as well as Sall1 and Pax2, encoding key transcription factors; WT1 drives MM differentiation and mesenchyme-epithelial transition by targeting Fgf8 and Wnt4; WT1 defines podocyte identity by activation of other podocyte-specific transcription factors, including Mafb, Lmx1b, FoxC2, and Tcf21.
107	26458176	By recapitulating metanephric kidney development in vitro, we generate SIX2+ SALL1+ WT1+ PAX2+ NPCs with 90% efficiency within 9 days of differentiation.
108	27588086	In addition, the expression of octamer-binding transcription factor 4 (Oct-4), a stem cell marker, was detected and suggested that kidney-specific stem cells were present in the DT-treated tissue samples.
109	27588086	The unique cells were positive for Oct-4 and Pax-2; thus suggesting that the identified cells were kidney-derived stem cells.
110	28852936	Subsequently, thus-obtained Osr1⁺ cells were induced further with activin-A (10 ng/ml), RA (10 ng/ml), BMP-7 (2.5 ng/ml), EGF (30 ng/ml) and bFGF (30 ng/ml) for 9 days.
111	28852936	Consequently, differentiated cells were immunopositive for anti-podocin, anti-synaptopodin and anti-GLEPP1 monoclonal antibodies.
112	28852936	These cells showed expression of early podocyte markers PAX2 and Wt1 at day 3 followed by day 6 and mature podocyte markers NPHS1, SULT1B1, NPHS2 and Synaptopodin at day 9.
113	29307170	Immunohistochemical staining for PAX-2, Ki-67, and synaptopodin was performed to evaluate cell proliferation in the kidney tissues.Results: After 4 weeks of treatment, islet transplantation significantly alleviated damage to the podocytes and increased the number of glomerular transition cells compared to the DN and IN groups, which were defined as cells that double-stained for PAX-2 and synaptopodin in membranous nephropathy.
114	29357419	Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu.
115	29357419	HG-induced DPD dedifferentiation manifested in the form of downregulation of Wilms' tumor 1 (WT1) and upregulation of paired box 2 (PAX2) expression.
116	29357419	WT1-silenced DPDs displayed enhanced expression of PAX2.
117	29357419	Immunoprecipitation of DPD cellular lysates with anti-WT1 antibody revealed formation of WT1 repressor complexes containing Polycomb group proteins, enhancer of zeste homolog 2, menin, and DNA methyltransferase (DNMT1), whereas silencing of either WT1 or DNMT1 disrupted this complex with enhanced expression of PAX2.
118	29357419	HG downregulated DPD expression of APOL1. miR193a-overexpressing DPDs displayed downregulation of APOL1 and enhanced expression of dedifferentiating markers; conversely, silencing of miR193a enhanced the expression of APOL1 and preserved DPD phenotype.
119	29357419	Moreover, stably APOL1G0-overexpressing DPDs displayed the enhanced expression of WT1 but attenuated expression of miR193a; nonetheless, silencing of APOL1 reversed these effects.
120	29357419	Vitamin D receptor agonist downregulated miR193a, upregulated APOL1 expression, and prevented dedifferentiation of DPDs in HG milieu.
121	29357419	Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu.
122	29357419	HG-induced DPD dedifferentiation manifested in the form of downregulation of Wilms' tumor 1 (WT1) and upregulation of paired box 2 (PAX2) expression.
123	29357419	WT1-silenced DPDs displayed enhanced expression of PAX2.
124	29357419	Immunoprecipitation of DPD cellular lysates with anti-WT1 antibody revealed formation of WT1 repressor complexes containing Polycomb group proteins, enhancer of zeste homolog 2, menin, and DNA methyltransferase (DNMT1), whereas silencing of either WT1 or DNMT1 disrupted this complex with enhanced expression of PAX2.
125	29357419	HG downregulated DPD expression of APOL1. miR193a-overexpressing DPDs displayed downregulation of APOL1 and enhanced expression of dedifferentiating markers; conversely, silencing of miR193a enhanced the expression of APOL1 and preserved DPD phenotype.
126	29357419	Moreover, stably APOL1G0-overexpressing DPDs displayed the enhanced expression of WT1 but attenuated expression of miR193a; nonetheless, silencing of APOL1 reversed these effects.
127	29357419	Vitamin D receptor agonist downregulated miR193a, upregulated APOL1 expression, and prevented dedifferentiation of DPDs in HG milieu.
128	29357419	Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu.
129	29357419	HG-induced DPD dedifferentiation manifested in the form of downregulation of Wilms' tumor 1 (WT1) and upregulation of paired box 2 (PAX2) expression.
130	29357419	WT1-silenced DPDs displayed enhanced expression of PAX2.
131	29357419	Immunoprecipitation of DPD cellular lysates with anti-WT1 antibody revealed formation of WT1 repressor complexes containing Polycomb group proteins, enhancer of zeste homolog 2, menin, and DNA methyltransferase (DNMT1), whereas silencing of either WT1 or DNMT1 disrupted this complex with enhanced expression of PAX2.
132	29357419	HG downregulated DPD expression of APOL1. miR193a-overexpressing DPDs displayed downregulation of APOL1 and enhanced expression of dedifferentiating markers; conversely, silencing of miR193a enhanced the expression of APOL1 and preserved DPD phenotype.
133	29357419	Moreover, stably APOL1G0-overexpressing DPDs displayed the enhanced expression of WT1 but attenuated expression of miR193a; nonetheless, silencing of APOL1 reversed these effects.
134	29357419	Vitamin D receptor agonist downregulated miR193a, upregulated APOL1 expression, and prevented dedifferentiation of DPDs in HG milieu.
135	34411489	miR-193a as a potential mediator of WT-1/synaptopodin in the renoprotective effect of Losartan on diabetic kidney.
136	34411489	Next, immunohistochemistry and immunofluorescence were used to detect Wilms tumor protein 1 (WT-1) and synaptopodin expression, respectively.
137	34411489	Protein levels of WT-1, synaptopodin, claudin1, and Pax-2 were assessed by Western blotting and real-time PCR.
138	34411489	In addition, Losartan significantly upregulated the immunopositive cell numbers of WT-1, the expression of WT-1 and synaptopodin in renal tissue.
139	34411489	By contrast, expression of claudin1 and Pax-2 in renal tissue were decreased in db/db-losartan group.
140	34411489	miR-193a as a potential mediator of WT-1/synaptopodin in the renoprotective effect of Losartan on diabetic kidney.
141	34411489	Next, immunohistochemistry and immunofluorescence were used to detect Wilms tumor protein 1 (WT-1) and synaptopodin expression, respectively.
142	34411489	Protein levels of WT-1, synaptopodin, claudin1, and Pax-2 were assessed by Western blotting and real-time PCR.
143	34411489	In addition, Losartan significantly upregulated the immunopositive cell numbers of WT-1, the expression of WT-1 and synaptopodin in renal tissue.
144	34411489	By contrast, expression of claudin1 and Pax-2 in renal tissue were decreased in db/db-losartan group.